The Weight-Loss Pill Era: Novo's Wegovy Tablet Tops Three Million Scripts.

Novo Nordisk (NVO) said prescriptions for its Wegovy weight-loss pill have surpassed three million — a big number for an oral version of a treatment that until recently mostly meant injections.

Based on WSJ reporting · Capital Wealth analysis by Sean Anees Saifi · June 9, 2026

A modern pharmacy counter with neatly arranged unlabeled white pill bottles.

The Story

Novo Nordisk (NVO) said prescriptions for its Wegovy weight-loss pill have surpassed three million — a big number for an oral version of a treatment that until recently mostly meant injections. A pill is far easier to start and stick with, which is how a good drug becomes a blockbuster. The flip side showed elsewhere in the race: Zealand Pharma fell after nearly a fifth of patients in a late-stage obesity-shot study dropped out over gastrointestinal side effects.

What This Means For The Book

The GLP-1 wave remains one of the strongest secular growth stories in healthcare. We get our exposure through the two leaders — Novo Nordisk (NVO) and Eli Lilly (LLY) — both reinforced, and we watch the also-rans for stumbles.

Themes & Tickers In This Article

NVONovo Nordisk
LLYEli Lilly

Symbols are listed for reference. Not a recommendation. See Capital Wealth Model Portfolios for current allocations.

Q2 Review — 15 Minutes, Phone Or Zoom

Bring this article and your statement. We translate every market story into a position-level decision in your account.

Book Q2 Review →View Portfolios →